IMA203 anzutresgene autoleucel Updated Oct 25
The binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.
- Phase 1b data showed compelling efficacy: 56% confirmed ORR, 14.6-month mDOR, 16.2-month mOS in heavily pretreated metastatic melanoma at ASCO 2026, well above standard-of-care benchmarks in later-line melanoma (source: investors.immatics.com press release June 1, 2026)
- FDA granted RMAT designation (all Breakthrough Therapy benefits) and Orphan Drug designation for both cutaneous and uveal melanoma, providing regulatory acceleration and market exclusivity (source: germanupdate.com, investors.immatics.com)
- Strong analyst support: 15 of 16 analysts rate Buy/Strong Buy, mean price target ~$17.26 vs. $7.31 current price (~136% implied upside), with Stifel initiating at Buy as recently as Oct 14, 2026
- SUPRAME trial was already amended once because PFS events accrued slower than modeled, dropping the interim analysis raises uncertainty about effect size and could signal a smaller-than-hoped treatment benefit (source: peptideandprotein.com, biotechdistilled.substack.com)
- A competitor, Iovance's lifileucel (Amtagvi), is already FDA-approved for post-PD-1 melanoma since Feb 2024, and TIL therapy is one of the investigator's choice arms in SUPRAME, setting a high efficacy bar (source: FDA.gov, clinicaltrials.gov)
- As a single-dose autologous cell therapy, manufacturing complexity, vein-to-vein time, and cost could limit commercial adoption vs. off-the-shelf alternatives (source: Nature Medicine paper on IMA203)